| Yasir Shareef, DO | |
|
10238 E Hampton Ave Ste 205, Mesa, AZ 85209-3318 | |
| (480) 354-6463 | |
| Not Available |
| Full Name | Yasir Shareef |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 22 Years |
| Location | 10238 E Hampton Ave Ste 205, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336178235 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yuma Regional Medical Center | Yuma, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yuma Regional Medical Center | 2062314826 | 288 |
News Archive
Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
When communicating with white patients, black physicians may face greater challenges than their white counterparts, according to a University of South Carolina study.
The Senate Finance Committee handed a major victory to the health care industry Tuesday by voting down two proposals that would have created a "public option" to compete against private health insurance providers as part of an overhaul of the nation's health care system. The industry has fought the public option with lobbying expenses and campaign contributions since the beginning of the year, fearing that the proposed policy would cut into their record profits.
› Verified 8 days ago
| Entity Name | Yuma Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194706655 PECOS PAC ID: 2062314826 Enrollment ID: O20040122000526 |
News Archive
Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
When communicating with white patients, black physicians may face greater challenges than their white counterparts, according to a University of South Carolina study.
The Senate Finance Committee handed a major victory to the health care industry Tuesday by voting down two proposals that would have created a "public option" to compete against private health insurance providers as part of an overhaul of the nation's health care system. The industry has fought the public option with lobbying expenses and campaign contributions since the beginning of the year, fearing that the proposed policy would cut into their record profits.
› Verified 8 days ago
| Entity Name | Mind Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699973628 PECOS PAC ID: 3577657931 Enrollment ID: O20070917000543 |
News Archive
Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
When communicating with white patients, black physicians may face greater challenges than their white counterparts, according to a University of South Carolina study.
The Senate Finance Committee handed a major victory to the health care industry Tuesday by voting down two proposals that would have created a "public option" to compete against private health insurance providers as part of an overhaul of the nation's health care system. The industry has fought the public option with lobbying expenses and campaign contributions since the beginning of the year, fearing that the proposed policy would cut into their record profits.
› Verified 8 days ago
| Entity Name | Tucson Physician Group Holdings Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356726939 PECOS PAC ID: 0547560070 Enrollment ID: O20151204001261 |
News Archive
Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
When communicating with white patients, black physicians may face greater challenges than their white counterparts, according to a University of South Carolina study.
The Senate Finance Committee handed a major victory to the health care industry Tuesday by voting down two proposals that would have created a "public option" to compete against private health insurance providers as part of an overhaul of the nation's health care system. The industry has fought the public option with lobbying expenses and campaign contributions since the beginning of the year, fearing that the proposed policy would cut into their record profits.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yasir Shareef, DO Po Box 8323, Scottsdale, AZ 85252-8323 Ph: (832) 721-4402 | Yasir Shareef, DO 10238 E Hampton Ave Ste 205, Mesa, AZ 85209-3318 Ph: (480) 354-6463 |
News Archive
Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
When communicating with white patients, black physicians may face greater challenges than their white counterparts, according to a University of South Carolina study.
The Senate Finance Committee handed a major victory to the health care industry Tuesday by voting down two proposals that would have created a "public option" to compete against private health insurance providers as part of an overhaul of the nation's health care system. The industry has fought the public option with lobbying expenses and campaign contributions since the beginning of the year, fearing that the proposed policy would cut into their record profits.
› Verified 8 days ago
Amol Rohit Patel, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2028 | |
Dr. Kate Gillpatrick, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2000 | |
Nancy L Vander Veer, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 602-344-2002 Fax: 480-649-0783 | |
Dr. Yaniv Simon, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2026 Fax: 480-344-0219 | |
Dr. Samuel Hutchinson, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4135 S Power Rd, Mesa, AZ 85212 Phone: 480-397-2830 | |
Payam M Sadr, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2000 Fax: 480-649-0783 | |
Troy Michael Fulton, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3707 E Southern Ave, Mesa, AZ 85206 Phone: 480-509-7738 |